(Reuters) -Eli Lilly expects to begin promoting its weight-loss drug in Hong Kong as early as the top of this 12 months, Bloomberg Information reported on Sunday.

The drugmaker has acquired approval from the Hong Kong authorities to promote its tirzepatide injections — branded as Mounjaro — in a tool referred to as Kwikpen for each long-term weight administration and kind 2 diabetes, Eli Lilly (NYSE:) advised Bloomberg in an announcement.

Tirzepatide is the energetic ingredient within the U.S. agency’s diabetes drug Mounjaro, and weight-loss drug Zepbound.

Eli Lilly didn’t instantly reply to a Reuters request for remark.

The corporate had acquired approval from Chinese language regulators for its weight-loss drug tirzepatide in July, additional intensifying competitors with Danish rival Novo Nordisk (NYSE:) in the important thing Asian market.

Novo Nordisk and Eli Lilly are racing to extend manufacturing in a weight-loss market estimated to achieve not less than $100 billion globally by the top of the last decade.

Each firms’ weight problems therapies belong to a category of medicine initially developed for diabetes referred to as GLP-1 agonists.